Subject Index

A
Abiocor TAH, 353–354
Abiomed BVS 5000 system, 356
Abiomed devices, 345–347
Ablation catheters, 254–255
balloon catheter, 256
cryoablation, 256
disadvantage of irrigated, 253
radiofrequency, 255
ACEi, see Angiotensin converting enzyme inhibitors (ACEi) therapy
ACORN trial, 82
Action potentials (AP), prolonged, 18–19
Acute cardiogenic shock, 355–356
Tandemheart Percutaneous LVAD impact in, 356
Acute decompensated heart failure clinical trial design, 74–75
Adjunctive therapy, 288
Advanced decompensated HF invasive hemodynamic monitoring in, 133
safety and efficacy of PA catheter in, 132–133
Advanced heart failure (ACC/AHA stage D) definition, 340
heart transplantation for, 340
AF, see Atrial fibrillation (AF)
African-American Heart Failure Trial (A-HeFT), 48
Afterload, 3
AHA/ACC guidelines for pharmacotherapy of heart failure, 60
Aldosterone production, 11
Aldosterone receptor antagonists therapy with, 49–51
Alfieri repair, 320–321
Angiogenesis, 273
Angioplasty balloon, 264–265
percutaneous transluminal angioplasty (PTA), 288
for SFA disease, 292
percutaneous transluminal renal angioplasty (PTRA), 296
plain old balloon angioplasty (POBA), 264
Angiotensin converting enzyme inhibitors (ACEi) therapy, 11, 37–42, 306
major trials, 39–40
recommended doses, 41
Angiotensin receptor antagonists, 306
Angiotensin Receptor Blockers (ARBs) therapy, 42–47
recommended doses, 47
trials, 43–44
Antegrade approach to percutaneous heart valve (PHV) placement, 313, 314
Antiarrhythmic medications, 58
Anticoagulation, medical therapy, 56–57
Antitachycardia pacing, 226
Aortic stenosis mortality, 311
percutaneous treatment balloon aortic valvuloplasty, 312–313
indications for, 311–312
percutaneous aortic valve replacement, see Percutaneous aortic valve replacement symptoms, 311
Aortic valve replacement percutaneous approaches to, see Percutaneous aortic valve replacement
APDs, see Atrial premature depolarizations (APDs)
Arginine vasopressin (AVP) release, 12
Arrhythmia detection primary criterion for, 174
programmable detection criteria for, 174
Arrhythmogenesis, cardiac, see Cardiac arrhythmogenesis
Astronomer system, 252
Asymptomatic acute severe MR, surgical intervention for, 319–320
ATP-terminated ventricular tachycardia, stored electrogram of, 173
Atrial arrhythmias and implanted devices, interactions between, 216
mechanisms of, 216
Atrial arrhythmias (cont.)
rationale for automatic device treatment of, 227
termination of
atrial tachycardia, 226–227
cardioversion from implanted device, 227–228
Atrial fibrillation (AF), 20
catheter ablation of, see Catheter ablation of AF
complexity of, 217
device-based features in management of, 229
pacing algorithms to prevent, 224–226
in patients with pacemakers, see Atrial fibrillation in patients with pacemakers
prevalence in HF, 235–236
with rapid ventricular response, 174
treatment options
nonpharmacologic therapy, 237
pharmacologic therapy, 224–226
Atrial fibrillation in patients with pacemakers
diagnosis of
atrial high rate episodes, 220
implanted devices with atrial leads for, 219
incorrect device, 222
pacemakers for, 219–220
thromboembolic risk, 221
randomized prospective trials, 217–219
sinus node dysfunction, 219
ventricular pacing, 218
Atrial pacing
dual-site, 223–224
from interatrial septum near coronary sinus ostium, 222–223
multisite, 224
overdrive, 225–226
with pacemaker programming, 224–226
from right atrial appendage, 222–223
Atrial premature depolarizations (APDs), 216
Atrial tachyarrhythmias, 227
Atrial tachycardia, pace termination of, 227
Atrioventricular coordination, 187
Atrioventricular valve replacement, 329
AV delays, programmed
and hemodynamic parameters, 187
AV timing, 205–207
Axial flow pumps
DeBakey VAD®, 350–351
Heartmate II®, 351–352
Jarvik 2000®, 352
B
Balloon angioplasty, 264–265
Balloon catheters, 256
Balloon expandable pulmonary valve implantation, 307
Balloon-expandable stents
for iliac artery endovascular interventions, 291
for ostial renal artery disease locations, 296
Balloon mitral valvuloplasty (BMV)
indications for, 318–319
vs. open commissurotomy, 319
Basket catheters, 252–253
BENESTENT study, 266
Beta-adrenergic receptor antagonists, 51–56
recommended doses, 55
trials, 52–53
Beta-blockers (bB), see Beta-adrenergic receptor antagonists
Bioimpedance cardiography (ICG)
accuracy studies in heart failure, 145
in ambulatory HF patients, 144–145
of CO and TFC, 143
of ESCAPE trial, 143–144
fluid overload monitoring with, 146
Bioresorbable stents, 293
Biventricular (BiV) and LV pacing, 189
Biventricular support, 343
BLASTER trial, 292
BMV, see Balloon mitral valvuloplasty (BMV)
Boston Scientific system, 199
Bradycardia pacing
ICD programming for, 176–177
Brain natriuretic peptide (BNP)
levels and filling pressures, 122–124
Bridge to recovery (BTR)
for chronic disorder treatment, 360–361
conditions, 361
Bridge to transplant (BTT), 82–83, 84
devices, 99
patients, complications in, 358
trials, 357
infection in, 363–364
BTT, see Bridge to transplant (BTT)
C
Calcium channel blockers, 58
Calcium cycling
in normal and failing cardiac myocytes, 16–18
Candesartan Assessment of Reduction in Mortality and Morbidity-Alternative study (CHARM-Alternative), 42
Candesartan in Heart Failure—Assessment of Reduction in Mortality and Morbidity (CHARM) study, 236
Carbonic anhydrase inhibitors, 33
Cardiac arrhythmogenesis
molecular mechanisms affecting, 15–20
Cardiac index
  pulmonary capillary wedge pressure and, 4

Cardiac Insufficiency Bisoprolol Study (CIBIS II), 54

Cardiac output (CO), 124, 127

Cardiac restraint devices
  CorCap® device, 379–381
  Paracor® device, 381

Cardiac resynchronization therapy (CRT), 75–79
  adding new features to, 98
  clinical trials in
    atrial fibrillation, 198
    CARE-HF study, 194–195
    COMPANION trial, 194
    CONTAK CD trial, 194
    cost-effective analysis of, 198
    MIRACLE trial, 193
    MUSTIC, 191–192
    PATH-CHF study, 192–193
    patient characteristics in, 195–196
    QRS morphology in, 196–197
    results of, 197
  leads and delivery systems, 198–199
  long-term effect of, 188–189
  mitral regurgitation reduction by, 189
  placebo effect, 98
  recommendations for, 208–209
  roles of, 187

Cardiac resynchronization therapy (CRT) device systems, 98
  clinical changes in patients implanted with, 204
  clinical management of patients with, 205
  clinical studies, 105–106
  diagnostic options, 203–204
  hemodynamic changes in patients implanted with, 204
  LV pacing maximizing by, 201, 203
  pacing configurations, 201
  troubleshooting/optimization of
    AV timing, 205–207
    ECG patterns, 204–205
    VV timing, 207
  vs. CRT defibrillators, 204

CardioMEMS® wireless HF sensor, 140

Cardiopulmonary exercise (CPX) testing, 100–101
  challenges associated with use, 101
  procedure, 100–101

CardioWest TAH, 353–354, 360
  CARE-HF study of CRT, 194–195
  CARE-HF trial, 82

Carotid artery disease
  endovascular management of, 297

Carotid artery stenting (CAS)
  CMS reimbursement for, 299

high-risk features of patients enrolled in, 298–299

long-term durability of, 299

Carotid revascularization, 298

CARTO system
  catheter movement, 245
  disadvantages of, 247
  image of left atrium during pulmonary vein isolation, 247
  operating principle, 244–245
  spatial resolution, 246

Carvedilol Prospective Randomized Cumulative Survival Study Group (COPERNICUS), 54

Carvedilol trial, 54, 55

Catheter ablation of AF
  ablation catheters for, 254–255
  balloon catheter, 256
  cryoablation, 256
  disadvantage of irrigated, 253
  radiofrequency, 253
  Brockenbrough needle for, 242
  CARTO system for, 244–247
  clinical guidelines for, 239
  efficacy of, 238
  EnSite NavX system for, 247–249
  LACA procedure for, 237–238
  mechanical ICE for, 240–241
  multielectrode mapping catheters for, 251–253
  nonfluoroscopic three-dimensional mapping techniques for, see Nonfluoroscopic three-dimensional mapping techniques
  phased-array ICE for, 241–242
  remote magnetic catheter navigation, 249–250
  segmental pulmonary vein isolation procedure for, 237, 239
  transseptal puncture, 239, 240
  transseptal sheaths for, 242–244
  Catheter navigation system, 249–250
  CAVATAS trial, 298

Center for Devices and Radiological Health (CDRH)
  collaborative relationships with stakeholders, 112–113
  on data collection in postmarket setting, 97
  goal of, 90
  medical device regulation, 91

CFR 21
  HUD provision of, 94
  well-controlled clinical investigation, 97

Chronic intractable angina pectoris
  efficacy of spinal cord stimulation for, 274

Chronicle® IHM
  clinical trials in HF, 138–140
  components of, 135
Subject Index

Chronicle® IHM (cont.)
  data validation, 136–138
design, 135
  regression analyses relating pressures derived from, 139
  representative output from, 138
Chronic ventricular remodeling, in HF, 4–8
Circulatory System Devices Advisory Panel, role of, 111–112
Class I devices, 92
Class II devices, 92
Class III devices
  marketing of, 93
  PMA approval of, 94
Class III recall, 96
Class I recall, 96
Clinical events committee (CEC), 103–104
Clinical trial design, considerations in
  control population selection, 97
    active treatment control, 98–99
    CRT device, 98
    historical control, 99
    placebo control, 98
  endpoints selection
    all-cause mortality, 100
    CPX testing and, 100–101
    in device trials, 99–100
    EuroQol for, 102–103
    heart failure-related hospitalization, 100
    KCCQ instrument, 102
    MLHF questionnaire, 101–102
    6MW test, 101
    NYHA functional classification system for, 102
    in unblinded device trials, 103
  gender bias, 104–105
  missing data points, 104
  quality control measures, 103–104
Clinical trial design, device therapy, 69–85
  current designs in HF populations, 74–83
    acute decompensated heart failure, 74–83
    symptom relief, 74–75
    functional improvement, 75–83
    quality of life, 75–83
  elements of, 70–74
  impact on outcome, 83–84
  newer approaches for devices in HF patients, 85
COMPANION trial, 82, 194
COMPASS-HF trial, primary end-point in, 139
Compensatory systems, in HF, 2–15
  chronic ventricular remodeling, 4–8
  Frank–Starling mechanism, 3–4
  neurohormones, 8–15
  normal cardiac function, 2–3
Concentric left-ventricular hypertrophy, 5–6
Conduction, abnormalities in, 19–20
Connexin 43 (Cx43), 20
CONTAK-CD Focused Confirmatory Study design, 79
CONTAK CD trial, 194
Contrast-enhanced Doppler echocardiography, 142
Control group, for clinical trial, 73
Control population selection, 97
  active treatment control, 98–99
  CRT device, 98
  historical control, 99
  placebo control, 98
Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), 38, 41–42
CorCap® device, 379–381
Coronary artery disease
  and heart failure, 271–272
  no-option patients treatment
    enhanced external counterpulsation, 274–275
    spinal cord stimulation, 274
    therapeutic angiogenesis for, 273
    treatment by balloon angioplasty, 264–265
    treatment by stenting
      restenosis rate, lower, 266
      safety and efficacy, 265–266
Coronary sinus pacing
  over-the-wire leads for, 202
CORONA trial, 57
Critical limb ischemia (CLI), 288
CRT, see Cardiac resynchronization therapy (CRT)
Cryoablation, 256
Cryoplasty, 293
Cypher stent, 268–269

D
Debakey VAD®, 350–351
Destination therapy (DT), 83, 84, 361–363
  CMS and FDA-approved indications for, 363
  end-stage heart failure management by, 363
  FDA/CMS criteria for, 362
  morbidity and mortality, 363
Device manufacturer
  clinical trial design considerations, see
    Clinical trial design, considerations in
design controls, complying with, 91–92
510(k) submission prior to marketing, 92–93
Pre-IDE submissions, 95
quality system, 92
research and development costs, 94
Device therapy trials, 69–85
  for decompensated heart failure, 75
Subject Index

end-stage heart failure, 84
See also Clinical trial design, device therapy
Digitalis glycosides, 30–33
Digitalis Investigators Group (DIG) trial, 31–32
Digoxin, 30–33, 306
Diltiazem, 58
Diuretic therapy, 33–37, 121
Doppler-derived resistance index, 296
Doppler techniques
for hemodynamics monitoring, 142
Drug-eluting stents (DES)
complications with, 270–271
Cypher stent, 268–269
efficacy of, 271
Endeavor stent, 270
hepacoat stent, 267
paclitaxel, 268
rapamycin, 267–268
restenosis rates of, 266
TAXUS paclitaxel-eluting stent, 269–270
Drug interactions, with digoxin, 32
Dual-site atrial pacing, 223
Dyssynchrony
electrical timing, 187–188
imaging modalities to determine, 192
coronary sinus anatomy, 190–191
echocardiography, 190
mechanisms of, 187

E
Eccentric left-ventricular hypertrophy, 6–7
ECG patterns, 204–205
Echocardiography
for assessing RV and LV, 142
dyssynchrony assessment by, 190
Ectopic atrial foci, 216
Edge-to-edge repair, 320–324
Electroanatomic mapping systems, see Nonfluoroscopic three-dimensional mapping techniques
Electromagnetic interference (EMI), 175
Embolic protection devices (EPD)
variations in, 297
Endeavor stent, 270
Endovascular therapies
for carotid artery disease, 297–298
for occlusive atherosclerotic peripheral arterial disease, 288, 289
Endpoints selection
all-cause mortality, 100
CPX testing and, 100–101
in device trials, 99–100
EuroQol for, 102–103
heart failure-related hospitalization, 100
KCCQ instrument, 102
MLHF questionnaire, 101–102
6MW test, 101
NYHA functional classification system
for, 102
in unblinded device trials, 103
Enhanced external counterpulsation (EECP), 274–275
EnSite NavX system
advantages of, 248
disadvantage of, 249
noncontact mapping with, 248–249
operating principle, 247
Epicardial leads, 200–201
Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), 50, 51
ESCAPE trial, 122
Ethical challenges, for clinical trial, 74
EuroQol instrument, 102–103
Evaluation of Losartan In The Elderly Study (ELITE II) trial, 45
Evaluation Study of Congestive Heart Failure and Pulmonary Catheter Effectiveness (ESCAPE) trial, 127
criticisms of, 134
PA catheter monitoring and clinical assessment, 132
primary and secondary end-points from, 133
pulmonary capillary wedge pressure in, 134
“Event-driven” trials, 72
EVEREST I and EVEREST II trials, 324
Excimer-laser catheter, 293
Excisional atherectomy, 293
Extracorporeal membrane oxygenators (ECMO), 357

F
Federal Food, Drug, and Cosmetic Act (FFDCA), 90
section 201 of, 95
section 906 of, 96
Femoral–tibial bypass grafts, 294
Fibromuscular dysplasia (FMD), 295
recurrences after PTRA, 296
Fibrosis, 20
Filling pressures, elevated
and HF therapy, 120
laboratory evaluation of
BNP levels, 123
using intrathoracic impedance algorithms, 146–147
Focused ultrasound balloon catheters, 256
Food and Drug Administration (FDA), 90
clinical trial design, considerations in, see Clinical trial design, considerations in
Subject Index

Food and Drug Administration (cont.)
IDE application, 93
PMA application reviews, 94
regulation of medical devices marketing by, 92
Frank–Starling mechanism, in HF, 3–4
Functional improvement, clinical trial design, 75–83
Furosemide, 35

G
Good Manufacturing Practice (GMP) requirements
quality system, 91–92

H
Hammock effect, 309
Heart failure devices
approved as HUD, 94
FDA review process for
CRT devices, 105–106
hemodynamic monitoring techniques, 110–111
VADs and TAHs, 106–110
Heart failure device trials
for add-on features to already-approved device therapies, 98
missing data points, 104
MLHF questionnaire uses in, 101–102
Heart failure (HF), 1
advanced decompensated, 132
AF prevalence in, 235–236
causes of, 186
elevated filling pressures in, see Filling pressures, elevated
hemodynamics monitoring in, see Hemodynamics monitoring
hospitalization for, 120
ischemic heart disease, 271–272
jugular venous distention in, 121–122
medical therapies, 29–61, 186
mortality in, 186–187
PA catheters uses in, 126–127
pathogenesis of, 9
pathophysiology of, 1–2
atrial fibrillation, 20
cardiac arrhythmogenesis, molecular mechanisms affecting, 15–20
compensatory systems in, 2–15
prevalence of, 120, 186
SCD in, see Sudden cardiac death (SCD)
valvular heart disease and, 306
Heart failure-related hospitalization, 100
Heartmate II®, 351–352
Heartmate® LVAD, 348–349
Heartmate XVE, 360
Heart, stretch-induced signal transduction in, 375
Heart transplantation, 340
Hemodynamics monitoring
bedside assessment of, 123
congestion and PCWP, 120
depressed CO, 121
modalities
CardioMEMS® wireless HF sensor, 141
IHM, see Implantable hemodynamic monitors (IHM)
LAP sensing devices, 140–141
PA catheters, see Pulmonary artery (PA) catheters
non-invasive methods of, 141
bioimpedance cardiography, 142–147
echocardiography, 142
Valsalva maneuver, 147–149
physical exam findings, 121–122
HF, see Heart failure (HF)
HF therapy
filling pressures, lowering, 120
goals of, 120
Humanitarian device exemption (HDE) application, 94
and PMA application, 94–95
Humanitarian Use Device (HUD), 94
Hydralazine and isosorbide dinitrate (Hyd-Iso) combination therapy, 47–49
Hyperkalemia
diuretic therapy complication, 36
Hypertrophy, see Myocardial hypertrophy
Hypokalemia
diuretic therapy complication, 36
Hypomagnesemia
diuretic therapy complication, 36–37
Hyponatremia
diuretic therapy complication, 36

I
ICD, see Implanting cardioverter-defibrillator (ICD)
ICG, see Bioimpedance cardiography (ICG)
Iliac artery
patency rates, 290
Iliac artery endovascular interventions, stents for, 291
Iliac lesions, TASC working group classification of, 290
Impella Recover systems, 344–345
Implantable device therapies, 374
Implantable hemodynamic monitors (IHM), 134
CardioMEMS® wireless HF sensor, 140
Chronicle® IHM
clinical trials in HF, 138–140
components of, 135
data validation, 136–138
design, 135
regression analyses relating pressures derived from, 139
representative output from, 138
LAP sensing devices, 140–141
models of, 137
Implanting cardioverter-defibrillator (ICD)
arrhythmia detection by, see Arrhythmia
detection
chest roentgenograms of, 172
components of, 171
cost-effectiveness evaluation of, 170
electrode, 171
in end-of-life care, 178
environmental EMI source sensing by, 175–176
functions of, 171
high-energy defibrillation and, 172
implantation indications in HF
ACC/AHA/HRS guidelines, 167–169
CMS coverage requirements, 170
primary prevention trials, SCD, 159–165
secondary prevention trials, SCD, 156–159
malfunctions, 177–178
programming, 176–177
details for, 174
for SCD prevention in advanced HF
DEFINITE trial, 166
high-risk patient subsets, 166, 170
MADIT II trial, 166
SCD-HeFT trial, 165–166
shock, management of, 177
surface tracing recorded during testing of, 173
Infection
following VAD placement, 363–364
pathophysiology of, 364
risk factors for, 364
treatment strategies for, 364
Inflammatory cytokines, 15
In-stent restenosis, 266
Interleukin-1 (IL-1), 15
Intermittent claudication (IC), 288
Interventional cardiology, 271
Interventricular dyssynchrony, 187
correction of, 188
Intra-aortic balloon pump (IABP), 341
Intra-left ventricular dyssynchrony, 187
Invasive PCWP, 148
Investigational Device exemption (IDE) application, 93
Ischemic heart disease, 271–272
Ischemic mitral regurgitation, 319
J
Jarvik 2000®, 352
K
Kansas City Cardiomyopathy Questionnaire (KCCQ), 102
510(k) submission prior to marketing, 92–93
L
Labeling of device, 95–96
Laser atherectomy, 293
Left atrial pressure (LAP) sensing devices, 140–141
Left ventricular assist device (LVAD), 375–376
support
post-transplant benefit of pretransplant, 359
prior to heart transplantation, 358
therapy
predicting survival after, 354–355
Left ventricular device therapies
cardiac restraint devices
CorCap®, device, 379–381
Paracor®, device, 381
for left ventricular remodeling, 376–377
LV tethers, 378
for mitral valve interventions, 381–384
regulatory perspective, 384
socks, 378–379
Left ventricular dilatation
anatomic challenges associated with, 320
Left ventricular dysfunction
pathophysiological mechanisms of, 373–374
Left ventricular end-diastolic pressure, non-invasive measurement of, 147–148
Left ventricular neurysmectomy, 376
Left ventricular remodeling surgery, 376–377
Legally marketed device, 92–93
Levitronix CENTriMAG®, 346–347
LocaLisa system, 249
Loop diuretics, 34–36
Lower extremity PAD
aortoiliac occlusive disease
endovascular approach for, 289
iliac interventions, 290
femoropopliteal atherosclerotic disease
endovascular management of SFA disease, 292
surgical revascularization, 291
in infrapopliteal segment
revascularization, 294
surgical patency rates, 294–295
symptoms, 288
LVAD, see Left ventricular assist device (LVAD)
LV contraction, 187
LV dyssynchrony and QRS duration, relation between, 188
LV function
and filling pressures, 120
LV lead
examples, 200
placement in coronary sinus, 200
via over-the-wire technique, 199
selection factors, 201
sheaths and, 200
LV pacing
biventricular vs., 189
and dobutamine effects on ventricular and aortic pressure, 188–189
LV remodeling
definition, 377
device therapy for, 375–376
reversal of, 374
M
Magnetically levitated systems, 352–353
MCS, see Mechanical circulatory support (MCS)
Mean arterial pressure (MAP), 2
Mechanical circulatory support devices
axial flow pumps
DeBakey VAD®, 350–351
Heartmate II®, 351–352
Jarvik 2000®, 352
choice of, 343
clinical experiences
acute cardiogenic shock, 355–356
bridge to decision and bridge to bridge, 357
bridge to recovery, 360–361
bridge to transplantation, 357–360
destination therapy, 361–363
device dysfunction, 365–366
device failure, 365
infection, 363–364
postcardiotomy cardiogenic shock, 356–357
psychologic issues, 366
risk of bleeding after VAD placement, 365
thromboembolism, 365
first-generation devices, 342
functionality of, 342–343
long-term devices
Heartmate® LVAD, 348–349
Novacor®, 349–350
Thoratec IVAD and PVAD, 347
short-term device
Abiomed devices, 345–346
Impella Recover systems, 344–345
Levitonix CENTriMAG®, 346–347
Tandemheart Percutaneous Ventricular Assist®, 343–344
third-generation blood pumps, 352–353
VADs, see Ventricular assist devices (VADs)
Mechanical circulatory support (MCS)
components of, 341
devices, see Mechanical circulatory support devices
history of, 340–341
indications for, 354
passive form of, 341
patient and device selection for, 354–355
role in advanced heart failure, 340
Medical device
classification, 96
development
design controls, 91
GMP requirements, 91–92
510(k) submission for, 92–93
labeling, 95–96
nonclinical testing of, 92
recalls, 96
regulation of, 91
regulation of marketing of
IDE application, 93
510(k) submission, 92–93
PMA approval, 93–94
premarket vs. postmarket review, 97
TPLC of, 90–91
Medical Device Amendments of 1976, 90
Medical therapy, 29–61, 186
aldosterone receptor antagonists, 49–51
anticoagulation, 56–57
Beta-adrenergic receptor antagonists, 51–56
consensus statements, 60–61
digoxin glycosides, 30–33
diuretics, 33–37
medications to avoid, 58–60
statins, 57
vasodilator therapy, 37–49
Medtronic Attain® system, 199
Medtronic-hall mechanical valves, 354
MERIT-HF trial, 236
Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF), 54
Minnesota Living with Heart Failure (MLHF) questionnaire, 101–102
6-Minute Walk (6MW) test, 101
Mitral annuloplasty, 326
Mitral annulus
anatomy and pathology of, 321–322
Mitral regurgitation (MR), 189
anatomic challenges associated with, 320
percutaneous mitral valve repair of, 319–320
Mitral stenosis
causes of, 318
and valvuloplasty, 318–319
Mitral valve interventions, 381–384
Mitral valve repair, 334
Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trial, 193
Multicenter InSync Randomized Clinical Evaluation (MIRACLE) trial, 193
Multielectrode mapping catheters
for electrical mapping of pulmonary veins, 251–253
Multisite Stimulation in Cardiomyopathy (MUSTIC) trial, 191–192
Myocardial hypertrophy
and ventricular remodeling in HF, 5–8

N
Natriuretic peptide system, 14–15
Neurohormonal changes, in HF, 8–15
Arginine vasopressin (AVP) release, 12
inflammatory cytokines expression, 15
natriuretic peptide system, 14–15
nitric oxide (NO) activation, 13–14
renin–angiotensin–aldosterone system activation, 10–11
SNS activation, 9–10
New destination therapy devices, trials of, 98–99
New York Heart Association (NYHA) functional classification system, 102
Nitric oxide (NO) activation, 13–14
Nitroso-redox imbalance, 13–14
Nonfluoroscopic three-dimensional mapping techniques
CARTO system
catheter movement, 245
disadvantages of, 247
image of left atrium during pulmonary vein isolation, 247
operating principle, 244–245
spatial resolution, 246
EnSite NavX system
advantages of, 248
disadvantage of, 249
noncontact mapping with, 248–249
operating principle, 247
LocalLisa system, 249
Non-invasive hemodynamic variables, 142
Non-invasive ICG, 143
Novacor®, 349–350

O
Objective endpoint, 100
Occlusive atherosclerotic peripheral arterial disease, endovascular approaches to treat, 288
Occlusive coronary sinus venography, 199
Office of Device Evaluation (ODE), 95
Open carotid surgical repair for stroke prevention clinical trials for, 297
Open surgical revascularization, 289
Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist losartan (OPTIMAAL), 45
OptiVol fluid status monitoring, 147
OptiVol® alert, 148
Ostial renal artery disease locations, stent type for, 296
Overdrive atrial pacing algorithm, 225–226
Over-the-wire leads
for coronary sinus pacing, 202

P
Pacemaker programming
atrial pacing with, 224–226
Pacing Therapies in Congestive Heart Failure (PATH-CHF) study, 192–193
Paclitaxel, 268
Paracor® device, 381
Percutaneous annuloplasty procedures
coronary sinus approach, 327
E-valve clip and its delivery, 324
implantation of rod-like device in coronary sinus, 324
PTMA® device
components of, 325–327
delivery catheter, 326
testing in ovine model of mitral regurgitation, 327
Viking percutaneous mitral annuloplasty device
components of, 324
delivery system, 326
implantation and anchor placement, 324–325
Percutaneous aortic valve replacement, 330
trials of, 317–318
valve designs for, 313
self-expanding stent valve, 315–316
via antegrade transseptal approach, 313
hemodynamic compromise risk, 314–315
left ventricular ejection fraction, 314
via retrograde approach, 315
via transapical approach, 318
Percutaneous atriointerventricular valve replacement, 329–330
Percutaneous balloon valvotomy, ACC/AHA guidelines for, 331–333
Percutaneous commissurotomy, 318
Percutaneous coronary interventions (PCI)
balloon dilatation in, 264
vs. CABG, 272
Percutaneous endovascular treatment of RAS angioplasty, 296
blood pressure control, 296
clinical indications for, 295–296
renal artery revascularization, 296
Percutaneous intervention
for atherosclerotic disease of lower extremities, 288
Percutaneous mitral valve placement, trials of, 329
Percutaneous pulmonic valve implantation
clinical outcome, 307–310
historical perspective, 307
hybrid approach, 310–311
indications, 307
limitations, 310–311
valve design, 308
Percutaneous septal sinus shortening device, 328
Percutaneous transluminal angioplasty (PTA), 288
for SFA disease, 292
Percutaneous transluminal renal angioplasty (PTRA), 296
Percutaneous valve interventions, guidelines for, 330
Peripheral arterial disease (PAD)
acute limb ischemia, 289
lower extremity, see Lower extremity PAD as marker, 288
prevalence of, 287–288
symptomatic, 288
Plain old balloon angioplasty (POBA)
acute complications, 264
Post-approval study, 97
Postcardiotomy cardiogenic shock (PCCS), 356–357
Post-infarct left ventricular remodeling, 5, 7–8
Potassium-sparing diuretics, 33–34
Predictors of Response to CRT (PROSPECT) trial, 190
Pre-IDE submissions, 95
Premarket Approval (PMA) application of class III heart failure devices, 93–94
reviewing, 94
Pre-market clinical trials, 75, 76–77, 79, 80, 81
Pressure overload-induced concentric hypertrophy, 5–6, 7
Primary end-point of ESCAPE trial, 132–133
Primary prevention trials, 160–161
CABG Patch randomized patients, 165
DINAMIT, 165
MADIT, 159
MADIT II, 162
MUSTT, 159
SCD-HeFT, 162
VALIANT patients, 165
Primary valvular pathology
repair approaches
dedge-to-edge repair, 320–324
percutaneous annuloplasty procedures, see Percutaneous annuloplasty procedures
surgical intervention, 319
Prolonged QRS duration, 20
Pulmonary artery diastolic pressure (PAD), 135–136
Pulmonary artery (PA) catheters
components of, 124–125
discovery surrounding use of mortality rate, 127
indications for use of, 125
dyspnea symptoms, 126
intra-cardiac pressure waveforms derived from, 126
recommendations for use of, 133–134
safety and efficacy
in advanced decompensated HF, 132–133
randomized trials evaluating, 128–131
Swan-Ganz, 125
Pulmonary capillary wedge pressure cardiac index and, 4
Pulmonary capillary wedge pressure (PCW), 134
Pulmonic valvular disease, percutaneous treatment of
balloon valvotomy, 306–307
percutaneous pulmonic valve implantation
clinical outcome, 307–310
historical perspective, 307
hybrid approach, 310–311
indications, 307
limitations, 310–311
valve design, 308
Purkinje fibers, 19
Q
QRS duration, 188
prolonged, 20
Quality of life, clinical trial design, 75–83
R
Randomized Aldactone Evaluation Study (RALES), 51, 52
Randomized Assessment of Digoxin on Inhibitors of the Angiotensin- Converting Enzyme Study (RADIANCE), 31
Rapamycin, 267–268
RAS, see Renal artery stenosis (RAS)
REMATCH trial, 359, 361–362
Remodeling
chronic ventricular, 4–8
Remote magnetic catheter navigation, 249–250
Remote Robotic Navigation System, 250
Renal artery atherosclerosis, 296–297
Renal artery revascularization, 296
Renal artery stenosis (RAS)
  cause of, 295
  clinical clues to suggest, 295
  percutaneous endovascular treatment of angioplasty, 296
  blood pressure control, 296
  clinical indications for, 295–296
  renal artery revascularization, 296
  quality-randomized trials, 296–297
Renin–angiotensin–aldosterone system (RAAS)
  activation, 10–11
  inhibitors, 37
Restenosis, 266–267
treatment, 271
RethinQ study, 197
Retrograde approach to aortic valve placement, 315
Revascularization modes, 289
RF ablation, 253
RVOT disorders
  percutaneous approach for, 310
Ryanodine receptor (RyR), 17, 18
Secondary endpoint data, 100
Secondary end-point of ESCAPE trial, 132–133
Secondary prevention trials
  AVID registry, 159
  ICD therapy, 156
  randomized trials, 157–158
Second heart sound (P2), 121–122
Self-expanding stents
  for iliac artery endovascular interventions, 291
SFA disease
  DES for treatment of, 292–293
  endovascular management of, 292
  and restenosis, 293
SFA stenting, concurrent abciximab use in, 292
SilverHawk atherectomy catheter, 293
Sirolimus, see Rapamycin
Sirolimus-eluting stents, 268–269
SOLVD study, 236
Spinal cord stimulation (SCS), 274
Spironolactone, 11
SR Ca$^{2+}$-ATPase (SERCA), 16, 17
Statins therapy, 57
Statistical modeling, for clinical trial, 73–74
Stroke
  open carotid surgical repair for prevention of, 297
  Stroke volume
  and systemic vascular resistance, 3
Studies of Left Ventricular Dysfunction (SOLVD), 38
  Prevention trial, 235–236
Study population, 31, 71, 165
Study sample, 71, 105
Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT) trial, 127
Sudden cardiac death (SCD), 15–16
  causes of, 155–156
  prevalence of, 155
  primary prevention
  ICD for, 165–170
  in ischemic cardiomyopathy, 160–161
  in nonischemic cardiomyopathy, 162–164
  secondary prevention using ICD, see
  Secondary prevention trials
Superficial femoral artery (SFA)
  functional characteristics of, 291
  stenting
    adjunctive technologies, stents, 293–294
    and restenosis rates, 291–292
Surgical mitral annuloplasty, 327
Survival and Ventricular Enlargement (SAVE) trial, 38
Swan-Ganz pulmonary artery catheter, 125
Symptomatic acute severe MR, surgical intervention for, 319–320
Symptomatic PAD, 288
Systemic vascular resistance
  stroke volume and, 3
T
Tachyarrhythmia
  pace termination of, 226
  ventricular, see Ventricular tachyarrhythmias
Tandemheart Percutaneous Ventricular Assist®, 343–344
Taxol, see Paclitaxel
TAXUS I trial, 269
TAXUS IV trial, 270
TAXUS paclitaxel-eluting stent, 269–270, 271
Thiazide type diuretics, 33, 34, 36
Third heart sound (S3), 121
Thoracic impedance cardiography, 144
Thoratec IVAD and PVAD, 347
Thromboembolism, 365
Tissue Doppler imaging (TDI)
  dyssynchrony assessment by, 190
Total artificial hearts (TAHs)
  applications, 340
  history of, 341
  primary disadvantage of, 353
  types of, 353–354
Total Product Life Cycle (TPLC)
  medical devices, 90–91
Transvenous transseptal approach, 318–319
Tumor necrosis factor-α (TNF-α), 15
Two-dimensional echocardiography
dyssynchrony assessment by, 190
Type D lesions, 291

U
UNLOAD trial, 74

V
Valsalva maneuver
  arterial blood pressure response to, 147–148
Valsartan Heart Failure Trial (Val-HeFT), 45–46
Valsartan in Acute Myocardial Infarction
  (VALIANT) trial, 45
Valvular heart disease
  catheter-based devices for, 330
  and heart failure, 306
Valvular surgery, morbidity and mortality from,
  306
Vascular trauma, 316
Vasodilator therapy, 37–49
  ACE inhibitors (ACEi), 37–42
Vasodilator therapy in Heart Failure study
  (V-HeFT), 47, 48
Venous thromboembolism (VTE), 56–57
Ventricular assist devices (VADs), 99
  as BTT, 357–360
  circulations, 343
complications following placement of
device dysfunction, 365–366
device failure, 365
infection, 363–364
psychologic issues, 366
risk of bleeding, 365
continuous flow, 342
displacement pumps, 342
functions of, 340
insertion of short-term, 357
pulsatility, 342
weaning, pharmacologic management during,
  361
Ventricular remodeling, 4–5, 374
  See also Chronic ventricular remodeling
Ventricular tachyarrhythmias, 16
Ventricular tachycardia (VT), 155–156
  ATP-terminated, stored electrogram of, 173
  shock-terminated, stored electrogram of, 172
Verapamil, 58
VeriCor® device, 148
VV timing, 207

W
Warfarin and Antiplatelet Therapy in Chronic
  CHF (WASH), 57
Warfarin and Antiplatelet Therapy in Chronic
  CHF (WATCH), 57
Warfarin–Aspirin Reduced Cardiac Ejection
  Fraction (WARCEF), 57
Wavelet reentry, 221